TheEdgeResearch
Home / Stocks / DMAA

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

NASDAQ Financial Services Shell Companies
$10.71 ▼ -0.05%
Market Cap
$259.9M
Sector
Financial Services
Industry
Shell Companies
Beta
0.00
52-Wk Range
10.22-10.72
CEO
Roger Bendelac
Country
US
Currency
USD

Drugs Made In America Acquisition Corp. Ordinary Shares operates in the Shell Companies industry of the Financial Services sector, headquartered in New York, NY, US. The stock last traded at $10.71, down 0.05% on the session, giving a market capitalisation of $259.9M. On trailing twelve-month figures it carries a trailing P/E of 52.32, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
52.32
Price / Sales
0.00
Price / Book
1.05
EV / EBITDA
-98.91
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
0.03
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
2
IPO date
2025-01-27
Headquarters
New York, NY, US
About Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.

Comparable companies

Drugs Made In America Acquisition Corp. Ordinary Shares is most often compared with the following Financial Services names:

ALFLOKVMLACOYSERTACSIMATACHTACOTACOU
More research on DMAA
DMAA technical analysis DMAA TheEdge Score Compare against peers
Open full interactive analysis & DCF →